BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pfizer Inc. (PFE) Faces New Competitive Threat to Chantix; Sopharma's Generic Works Just as Well in Early Studies


9/29/2011 7:25:59 AM

Pfizer is facing a threat to its top-selling smoking cessation drug Champix from the Bulgarian company that has long marketed the low-cost off-patent medicine from which it was derived.

A clinical study financed by British charities and medical funding agencies concludes that Tabex, sold by Sofia-based Sopharma, is promising because it is as effective and much cheaper than alternative products used by smokers seeking to quit, such as Champix.


Read at Financial Times
Read at Fox News
Read at WebMD
Read at ABC News
Read at Business Week

 
 
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES